Marshall Wace’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.29M | Sell |
30,493
-289,517
| -90% | -$18.6M | ﹤0.01% | 1786 |
|
|
2026
Q1 | $18M | Sell |
320,010
-112,945
| -26% | -$7.36M | 0.02% | 741 |
|
|
2025
Q4 | $34.7M | Sell |
432,955
-30,850
| -7% | -$2.07M | 0.03% | 452 |
|
|
2025
Q3 | $22.6M | Sell |
463,805
-52,165
| -10% | -$3.23M | 0.02% | 601 |
|
|
2025
Q2 | $38.5M | Sell |
515,970
-132,675
| -20% | -$8.78M | 0.04% | 365 |
|
|
2025
Q1 | $41.2M | Buy |
648,645
+368,648
| +132% | +$25.1M | 0.05% | 322 |
|
|
2024
Q4 | $21.9M | Buy |
279,997
+57,116
| +26% | +$4.59M | 0.03% | 510 |
|
|
2024
Q3 | $17.9M | Buy |
222,881
+177,989
| +396% | +$14.4M | 0.02% | 545 |
|
|
2024
Q2 | $3.71M | Sell |
44,892
-36,503
| -45% | -$3.21M | 0.01% | 1122 |
|
|
2024
Q1 | $6.95M | Buy |
81,395
+27,018
| +50% | +$2.12M | 0.01% | 866 |
|
|
2023
Q4 | $4.65M | Buy |
54,377
+32,529
| +149% | +$2.81M | 0.01% | 938 |
|
|
2023
Q3 | $1.96M | Sell |
21,848
-50,905
| -70% | -$4.54M | ﹤0.01% | 1232 |
|
|
2023
Q2 | $6.19M | Buy |
+72,753
| New | +$6.15M | 0.01% | 931 |
|
|
2022
Q1 | – | Sell |
-103,583
| Closed | -$5.49M | – | 3600 |
|
|
2021
Q4 | $5.49M | Buy |
+103,583
| New | +$6.31M | 0.01% | 1285 |
|
|
2021
Q1 | – | Sell |
-10,459
| Closed | -$1.24M | – | 2627 |
|
|
2020
Q4 | $1.24M | Sell |
10,459
-76,452
| -88% | -$8.23M | 0.01% | 1126 |
|
|
2020
Q3 | $7.58M | Buy |
86,911
+48,779
| +128% | +$4.26M | 0.05% | 381 |
|
|
2020
Q2 | $3.42M | Buy |
+38,132
| New | +$3.85M | 0.02% | 601 |
|
|
2020
Q1 | – | Sell |
-3,583
| Closed | -$412K | – | 1813 |
|
|
2019
Q4 | $412K | Buy |
+3,583
| New | +$434K | ﹤0.01% | 1215 |
|
|
2019
Q3 | – | Sell |
-152,363
| Closed | -$18.3M | – | 1772 |
|
|
2019
Q2 | $18.3M | Buy |
152,363
+102,384
| +205% | +$10.1M | 0.15% | 146 |
|
|
2019
Q1 | $4.37M | Buy |
+49,979
| New | +$4.55M | 0.04% | 508 |
|
|
2018
Q3 | – | Sell |
-2,259
| Closed | -$203K | – | 1195 |
|
|
2018
Q2 | $203K | Sell |
2,259
-754
| -25% | -$63.7K | ﹤0.01% | 666 |
|
|
2018
Q1 | $220K | Buy |
+3,013
| New | +$207K | 0.01% | 510 |
|
|
2016
Q3 | – | Sell |
-25,949
| Closed | -$752K | – | 1014 |
|
|
2016
Q2 | $752K | Sell |
25,949
-46,822
| -64% | -$1.42M | 0.01% | 760 |
|
|
2016
Q1 | $2.55M | Buy |
+72,771
| New | +$2.35M | 0.02% | 507 |
|
Other funds holding HAE
AI
Marshall Wace's HAE Position: Q2 2026 in Review
Marshall Wace reduced its Haemonetics (HAE) stake by 90% in Q2 2026, selling an estimated $18.6M and leaving 30,493 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1786.
Marshall Wace first reported a position in HAE in Q1 2016 and has held it in 24 quarters since. The position peaked at $41.2M in Q1 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Marshall Wace held 30,493 shares of Haemonetics worth $2.29M as of Q2 2026.
- Marshall Wace sold 289,517 Haemonetics shares in Q2 2026, an estimated $18.6M.
- Haemonetics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1786 holding.
- Marshall Wace first reported a position in Haemonetics in Q1 2016 and has held it in 24 quarters since.
- Marshall Wace's Haemonetics position peaked at $41.2M in Q1 2025.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.